On March 20, 2025 Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, reported a Q4 and Full Year 2024 business update (Press release, Adaptimmune, MAR 20, 2025, View Source [SID1234651305]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise. The launch is going very well and each step in delivering this important medicine: activating our treatment network; identifying biomarker eligible patients; exceptional manufacturing quality and turn-around times, strengthens our sarcoma platform capabilities for both Tecelra and for lete-cel. These results give us confidence in our strategy to build value from our sarcoma franchise and our path to profitability in 2027. In the context of the current capital markets, we are assessing all strategic options to enable us to achieve these goals."
Tecelra launch momentum increasing – the first commercial product in Adaptimmune’s sarcoma franchise
● 20 Authorized Treatment Centers (ATCs) now accepting referrals
● On track to have the full network of approximately 30 ATCs open by end of 2025
● Apheresed 3 patients in 2024 and invoiced 2 with Q4 product revenue of $1.2m
● Apheresed 10 patients in 2025 to date
● Successful reimbursement with no denials to date
● 100% success rate in manufacturing to date with no capacity constraints
Lete-cel – the next product in Adaptimmune’s sarcoma franchise
● Pivotal trial met primary endpoint with 42% ORR including 6 complete responses (CTOS 2024)
● On track to initiate rolling BLA submission in late 2025; approval anticipated in 2026
● Lete-cel will expand the addressable patient population for sarcoma franchise